Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFUSE-AHF: Continuous vs intermittent intravenous furosemide in acute heart failure
2025-523589-26-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of furosemide in Acute Heart Failure (AHF) (2 arms), sponsored by Central Denmark Region. Primary endpoint: Net weight loss at 3 days after randomisation. Planned start Apr 2026; status: authorised.
02
Drugs
furosemide
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2025-523589-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523589-26-00.